EICHORPublic-registry site landscape for NCT04663282, “A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics”, a Type 2 Diabetes study sponsored by Jiangsu HengRui Medicine Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04663282 (registry record) |
| Study title | A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics |
| Official title | Evaluation of the Efficacy and Safety of INS068 Injection and Insulin Degludec Subcutaneous Injection Once Daily in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With One or Two Oral Antidiabetics (A Randomized, Open-Label, Two-Arm, Treat-to-Target, Parallel Controlled Trial) |
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Condition(s) | Type 2 Diabetes |
| Phase | PHASE2 |
| Listed sites | 35 |
| Site countries | United States, Australia, China |
Patient-friendly overview of this study: eichor.com/study/NCT04663282.
Eichor generates a preliminary site-risk snapshot for NCT04663282 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Type 2 Diabetes trials
← Eichor home · All tracked trials · Type 2 Diabetes studies · Weekly briefs
